Tumor marker prevalence, particularly that of CA-125, was extensively noted in our cohort, reflecting its established role as a primary biomarker for ovarian cancer detection and monitoring, as discussed by Scholler et al. (2007) [26]. This evidence concerns the gene MUC16 and neoplasm.